Loading...
Leadership 2018-10-15T23:37:56+00:00

Management Team

Dr. Xu has served on Cesca’s board of directors since March 2016. In November 2017, the board of directors elected Dr. Xu as President and Chief Executive Officer (CEO) (transitioning from interim Chief Executive Officer as of November 2016; he joined the Board of Directors in March 2016 and currently serves as Chairman of the Board). He brings to Cesca over 15 years of leadership experience in the biopharmaceutical industry and has contributed to numerous successful product launches. In 2009, Dr. Xu founded Boyalife Group, a China-based diversified life sciences holding company and is currently the principal shareholder of Cesca. Prior to founding Boyalife, Dr. Xu served as a project leader at Pfizer, as a director of research at two publicly-traded companies and as a vice president at Founder Group, a Chinese technology conglomerate focused on information technology, pharmaceuticals, real estate, finance, and commodities trading. Dr. Xu’s expertise spans several diverse therapeutic areas, including arthritis & inflammation, cardiovascular disease, autoimmunity, oncology and diabetes. He has authored over forty publications and has been recognized by numerous professional societies for his contributions to biomedical research. Dr. Xu received his Ph.D. in immunology from Washington University School of Medicine (St. Louis, USA) and an executive MBA from Emory University (Atlanta, USA)..
Mr. Coelho joined Cesca as chief technology officer from SynGen Inc. in July 2017, where he was CTO and co-founder. Mr. Coelho is an engineer and inventor who has been awarded more than 30 U.S. patents related to cell cryopreservation, cryogenic robotics, cell selection, blood protein harvesting, and surgical hemostasis.

Prior to cofounding SynGen, Mr. Coelho founded and ran several companies, including  Cesca’s device division, ThermoGenesis Corp., where he also served as chairman and chief executive officer. At ThermoGenesis, he led the development of many of the company’s key products, including the Thermoline ultra rapid blood plasma freezers and thawers, the CryoSeal automated system for preparing fibrin sealant from a surgical patient’s blood, the BioArchive robotic system for controlled-rate freezing and cryogenically archiving units of hematopoietic stem and progenitor cells (HSPCs) derived from placental/cord blood and the AutoXpress System, which automates the sterile harvesting of HSPCs from cord blood into a 25 ml dual-compartment freezing bag. The BioArchive® and AutoXpress® Systems have defined cGMP standards in cord blood processing and banking worldwide.

In 2002, Mr. Coelho initiated an effort to obtain federal funding sufficient to allow qualified public cord blood banks to build a substantial inventory of ethnically diverse, clinical grade, cord blood stem cell units for all patients in need. Passed unanimously by Congress and signed by President Bush on December 19, 2005, the “Stem Cell Therapeutic and Research Act of 2005” authorized and began financing of a national inventory of 150,000 units of cryopreserved, HLA typed, cord blood stem cells and a website that allowed transplant physicians to choose optimal stem cell units for the treatment of blood cancers such as leukemia, myeloma, and lymphoma; inherited immunodeficiencies and marrow failure disorders and inherited disorders or errors of metabolism. During this last decade, Mr. Coelho has gathered detailed knowledge of the practices of the major public and private cord blood banks in 30 countries and has developed working relationships with many scientists, clinicians and directors associated with these cord blood banks.

As CTO of Cesca, Mr. Coehlo is leading the development of new products for the clinical and research fields that improve the speed and efficiency of harvesting target cell populations resident within peripheral or placental/cord blood or bone marrow and washing/purifying ex-vivo expanded cell populations derived from those cells.

Mr. Coelho holds a Bachelor’s degree in mechanical engineering from the University of California, Davis.

Ms. Zhu currently serves as general manager for the Company’s ThermoGenesis device division. Since joining in 2004, Ms. Zhu has contributed significantly to the establishment of ThermoGenesis’ commercial presence in China. Ms. Zhu has over 20 years of technical and sales experience in stem cell research. She started her career as a research scientist at Harvard Medical School Stem Cell Lab and BioTransplant, Inc. Ms. Zhu graduated from the Shanghai University of Science & Technology with a degree in biology and also studied statistics at Boston University.
Mr. Cauble, principal accounting officer, joined Cesca in 2010 and has served in various accounting management positions of increasing responsibility. Mr. Cauble has over 19 years of accounting experience in various financial and managerial roles for companies such as Diamond Foods Inc. and E.&J. Gallo Winery. Mr. Cauble obtained a B.S. in accounting and finance from the University of Idaho and is a certified public accountant.